Atezolizumab for advanced lung cancer with high PD-L1
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called atezolizumab, which helps the immune system fight cancer, for people with advanced lung cancer (non-small cell lung cancer) that has not been treated yet. It is for tumors with high levels of PD-L1, a protein that can help cancer hide from the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic non-small cell lung cancer that has not been treated with systemic therapy for metastatic disease.
- Your tumor tests positive for PD-L1 with a score of 50% or higher.
- You are able to perform daily activities with minimal assistance (ECOG performance status 0-2).
- You do not have a genetic mutation (like EGFR or ALK) that can be treated with targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
This trial is testing a combination of two drugs, cabozantinib and atezolizumab, for people with advanced lung cancer that has low PD-L1 levels. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
This trial tests a new drug combination (BL-M14D1 and Atezolizumab) for people with extensive-stage small cell lung cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow the growth of the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.